Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

被引:92
作者
Blechacz, Boris
Splinter, Patrick L.
Greiner, Suzanne
Myers, Rae
Peng, Kah-Whye
Federspiel, Mark J.
Russell, Stephen J.
LaRusso, Nicholas F.
机构
[1] Mayo Clin, Ctr Basic Res Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin, Mol Med Program, Rochester, MN 55905 USA
关键词
D O I
10.1002/hep.21437
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The oncolytic measles virus Edmonston strain (MV-Edm), a nonpathogenic virus targeting cells expressing abundant CD46, selectively destroys neoplastic tissue. Clinical development of Mv-Edm would benefit from noninvasive monitoring strategies to determine the speed and extent of the spread of the virus in treated patients and the location of virus-infected cells. We evaluated recombinant NW-Edrn expressing carcinoembryonic antigen (CEA) or the human sodium iodide symporter (hNIS) for oncolytic potential in hepatocellular carcinoma (HCC) and efficiency in tracking viruses in vivo by noninvasive monitoring. CD46 expression in human HCC and primary hepatocytes was assessed by flow cytometry and immunohistochemistry. Infectivity, syncytium formation, and cytotoxicity of recombinant MV-Edm in HCC cell lines were evaluated by fluorescence microscopy, crystal violet staining, and die NITS assay. Transgene expression in HCC cell lines after infection with recombinant NW-Edm in vitro and in vivo was assessed by CEA concentration, I-125-uptake, and I-123-imaging studies. Toxicology studies were performed in Ifnar(KO) X CD46 transgenic mice. The CD46 receptor was highly expressed in HCC compared to nonmalignant hepatic tissue. Recombinant MV-Edm efficiently infected HCC cell lines, resulting in extensive syncytium formation followed by cell death. Transduction of HCC cell lines and subcutaneous HCC xenografts with recombinant MV-Edm resulted in high-level expression of transgenes in vitro and in vivo. MV-Edm was nontoxic in susceptible mice. Intratumoral and intravenous therapy with recombinant MV-Edm resulted in inhibition of tumor growth and prolongation of survival with complete tumor regression in up to one third of animals. In conclusion, engineered NW-Edrn may be a potent and novel cancer gene therapy system for HCC. MV-Edm expressing CEA or hNIS elicited oncolytic effects in human HCC cell lines in vitro and in vivo, enabling the spread of the virus to be monitored in a noninvasive manner.
引用
收藏
页码:1465 / 1477
页数:13
相关论文
共 50 条
  • [41] The Preclinical Safety Study of the novel polymer coated oncolytic measles virus
    Takishima, Yuto
    Miyamoto, Shohei
    Hamada, Katsuyuki
    Sagara, Miyako
    Nosaki, Kaname
    Hijikata, Yasuki
    Okazaki, Toshihiko
    Yamada, Kazunari
    Kohara, Hiroshi
    Tani, Kenzaburo
    CANCER SCIENCE, 2018, 109 : 1152 - 1152
  • [42] Oncolytic virus VG161 in refractory hepatocellular carcinoma
    Yinan Shen
    Xueli Bai
    Qi Zhang
    Xingmei Liang
    Xinyan Jin
    Zeda Zhao
    Wei Song
    Qian Tan
    Ronghua Zhao
    William Jia
    Shanzhi Gu
    Guoming Shi
    Ziwei Zheng
    Guyue Wei
    Youlei Wang
    Tian Fang
    Yuwei Li
    Zijun Wang
    Zifan Yang
    Sida Guo
    Danni Lin
    Fang Wei
    Lei Wang
    Xiaoli Sun
    Aijun Qin
    Longshen Xie
    Yeting Qiu
    Wenqing Bao
    Shah Rahimian
    Manu Singh
    Yanal Murad
    Jianying Shang
    Min Chu
    Maoliang Huang
    Jun Ding
    Wei Chen
    Yufu Ye
    Yiwen Chen
    Xiang Li
    Tingbo Liang
    Nature, 2025, 641 (8062) : E5 - E5
  • [43] INTERACTION OF IMMUNE SYSTEM WITH ONCOLYTIC MEASLES VIRUS 'THERAPY IN AN MV SENSITIVE IMMUNOCOMPETENT MURINE MODEL OF MEDULLOBLASTOMA
    Lal, Sangeet
    Mueller, Sabine
    Gupta, Nalin
    Raffel, Corey
    NEURO-ONCOLOGY, 2019, 21 : 117 - 117
  • [44] Intraperitoneal therapy of ovarian cancer using an engineered measles virus
    Peng, KW
    TenEyck, CJ
    Galanis, E
    Kalli, KR
    Hartmann, LC
    Russell, SJ
    CANCER RESEARCH, 2002, 62 (16) : 4656 - 4662
  • [45] Characterization of a Novel Oncolytic Virus for Cancer Therapy
    Ravichandran, Abirami
    Nissly, Ruth H.
    Chothe, Shubhada
    Jakka, Padmaja
    Kuchipudi, Suresh V.
    FASEB JOURNAL, 2022, 36
  • [46] A viral attack on brain tumors: the potential of oncolytic virus therapy
    Mokhtarpour, Kasra
    Akbarzadehmoallemkolaei, Milad
    Rezaei, Nima
    JOURNAL OF NEUROVIROLOGY, 2024, 30 (03) : 229 - 250
  • [47] Sindbis virus as an oncolytic viral therapy for metastatic colorectal cancer
    Liu, Yuecheung
    Gu, Youling
    Li, Chao
    CANCER RESEARCH, 2009, 69
  • [48] Oncolytic Vaccinia Virus Therapy of Salivary Gland Carcinoma
    Chernichenko, Natalya
    Linkov, Gary
    Li, Pingdong
    Bakst, Richard L.
    Chen, Chun-Hao
    He, Shuangba
    Yu, Yong A.
    Chen, Nanhai G.
    Szalay, Aladar A.
    Fong, Yuman
    Wong, Richard J.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2013, 139 (02) : 173 - 182
  • [49] Gene therapy of viral hepatitis and hepatocellular carcinoma
    Ruiz, J
    Qian, C
    Drozdzik, M
    Prieto, J
    JOURNAL OF VIRAL HEPATITIS, 1999, 6 (01) : 17 - 34
  • [50] Oncolytic virus therapy using genetically engineered herpes simplex viruses
    Todo T.
    Human Cell, 2002, 15 (3) : 151 - 159